Wednesday 27th August 2025
Dapagliflozin 5mg and 10mg tablets reimbursement prices have decreased following a move from Category C to Category M in the September 2025 Drug Tariff. This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga®. More information on the change from Category C to M can be found here.
The September 2025 Drug Tariff reimbursement prices for Dapagliflozin are:
Dapagliflozin 5mg tablets – price decrease from £36.59 to £25.89
Dapagliflozin 10mg tablets – price decrease from £36.59 to £30.15
Previously, all branded and generically written prescriptions for Dapagliflozin tablets were reimbursed in line with NHS list prices of the brand Forxiga®. However, from September 2025, reimbursement of generically written prescriptions for Dapagliflozin tablets will be based on the Category M prices published in the September 2025 Drug Tariff. The Category M prices are calculated using actual market data obtained from suppliers.
The Department of Health and Social Care (DHSC) is making these changes outside the usual Category M quarterly cycle (Category M prices are normally updated every quarter in January, April, July, and October). All other July to September 2025 Category M prices will remain unchanged. DHSC was unable to give advance notice of these changes in the August Drug Tariff as the generic versions entered the market at the beginning of August.
Note: All generic Dapagliflozin prescriptions submitted in August will continue to be reimbursed in line with the August 2025 Drug Tariff. All branded prescriptions will continue to be reimbursed in line with the NHS list prices of Forxiga®.
Wednesday 27th August 2025